Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
June 21, 2023 07:30 ET
|
Arbutus Biopharma Corporation
Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...